Conclusions
toxicity
METASTATIC BREAST CANCER
The addition of aromatase inhibitor to oral vinorelbine over oral vinorelbine alone in aromatase inhibitor resistant metastatic breast cancer was associated with a non-significant improvement of PFS. The study has been prematurely stopped due to treatment toxicity. Several unexpected SAEs were reported. Metronomic oral vinorelbine schedule, at 50 mg three times a week, requires close biological monitoring. The question of hormonal treatment and chemotherapy combination remains open.
